<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04214873</url>
  </required_header>
  <id_info>
    <org_study_id>Focus-PiQo4 POH-19-03</org_study_id>
    <nct_id>NCT04214873</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effectiveness of the PiQo4 System for Reduction of Infra-orbital Pigmentation</brief_title>
  <official_title>A Pilot Study to Evaluate the Effectiveness of the PiQo4 Picosecond Laser (PSL) System for Reduction of Infra-orbital Pigmentation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Focus Medical, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Focus Medical, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 10 healthy subjects at a single site, aged 18-65 years old and Fitzpatrick skin&#xD;
      type I-IV with mild to moderate infra-orbital hyperpigmentation on the background of&#xD;
      epidermal and/or dermal pigmentation that wish to improve their POH&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in POH severity</measure>
    <time_frame>3 month follow up</time_frame>
    <description>POH improvement of at least 1 point evaluated by the investigator at the 3-month follow up compared to baseline using the POH severity in comparison to surrounding skin scale where score of between 0 and 4 will be assigned (0-Normal (Skin color comparable to other facial skin areas); 1- Trace (Faint pigmentation of infraorbital fold (bilateral)); 2- Mild (Pigmentation more pronounced); 3- Moderate (Deep dark colour, all four lids involved): ; 4 - Marked (Grade 3 + pigmentation spreading beyond infraorbital fold)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aesthetic improvement</measure>
    <time_frame>3 month follow up</time_frame>
    <description>Aesthetic improvement evaluated by the investigator at the 3-month follow up compared to baseline using a 5-point improvement scale (GAIS) where a score of between 0 and 4 will be assigned (0-Worse (The appearance is worse than the original condition.); 1- No Change (The appearance is essentially the same as the original condition); 2- Improved (Obvious improvement in appearance from initial condition, but a touch-up or re-treatment is indicated.); 3- Much improved (Marked improvement in appearance from initial condition, but not completely optimal. A touch-up would slightly improve the result.); 4 - Very much improved (Optimal result)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>POH</condition>
  <arm_group>
    <arm_group_label>POH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of POH Using PiQo4 Laser System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PiQo4 Laser System</intervention_name>
    <description>PiQo4 Laser System for treatment of POH</description>
    <arm_group_label>POH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Females or males&#xD;
&#xD;
          2. Age 18-65&#xD;
&#xD;
          3. Fitzpatrick skin types I-IV&#xD;
&#xD;
          4. POH on the background of epidermal and/or dermal pigmentation&#xD;
&#xD;
          5. POH severity - mild to moderate&#xD;
&#xD;
          6. Able to read, understand and provide written Informed Consent.&#xD;
&#xD;
          7. Able and willing to comply with the treatment/follow-up schedule and post treatment&#xD;
             care&#xD;
&#xD;
          8. Agreed to use the same facial skin care products during the clinical trial period&#xD;
             (including the follow-up period)&#xD;
&#xD;
          9. Agreed to the prohibition of the use of local/systemic corticosteroids or retinoids&#xD;
             and other local/systemic lightening medications, and willing to abide by such&#xD;
             instructions&#xD;
&#xD;
         10. Agreed to the daily use of an over SPF 50 sunblock on their face during the clinical&#xD;
             trial period (including the follow-up period), and willing to abide by such&#xD;
             instructions&#xD;
&#xD;
         11. Agreed to have their face photographed and willingness to allow Focus Medical (the&#xD;
             study Sponsor) and Lumenis and the investigators to use de-identified photographs of&#xD;
             the treated area for presentation and publication purposes&#xD;
&#xD;
         12. Women of childrearing potential (not postmenopausal [no menstrual cycle for at least&#xD;
             12 months], without an uterus and/or both ovaries, or has had a bilateral tubal&#xD;
             ligation)&#xD;
&#xD;
             *(In case of women of childbearing potential) Tested negative in the pregnancy test&#xD;
             and agreed to use birth control measures during the clinical trial period including&#xD;
             use of contraceptives (see list below) IUD, Double-Barrier Method, Vasectomized&#xD;
             Partner, No Heterosexual Intercourse, etc&#xD;
&#xD;
         13. Agreed not to undergo any other procedure on their face during their participation in&#xD;
             the clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breastfeeding&#xD;
&#xD;
          2. Inability to comply with all study protocols and regulations&#xD;
&#xD;
          3. Participation in a study of another device or drug&#xD;
&#xD;
          4. Heavy smokers and/or drinkers (those who smoke 25 or more cigarettes a day and/or ⩾8&#xD;
             drinks a week for women, and ⩾15 for men)&#xD;
&#xD;
          5. Application of any energy device treatment to the infraorbital region within 3 months&#xD;
&#xD;
          6. Application of any dermal filler to the infraorbital region within 6 months&#xD;
&#xD;
          7. Facial resurfacing, deep chemical peels, or taking oral retinoids within 6 months&#xD;
&#xD;
          8. Microdermabrasion (light or medium skin peel) treatment within 30 days&#xD;
&#xD;
          9. Chemical peel, systemic steroids, non-ablative laser, light, or radiofrequency&#xD;
             treatment within 3 months&#xD;
&#xD;
         10. Use of topical lightening agents or retinoids within 14 days&#xD;
&#xD;
         11. Any planned surgical intervention to the face for the duration of the trial&#xD;
&#xD;
         12. Use of Latisse, Revitalash, or other lash enhancement stimulators as well as&#xD;
             Bimatoprost in the previous 1 month&#xD;
&#xD;
         13. Presence of open wounds, lesions, or scarring in the area&#xD;
&#xD;
         14. Very thin skin (skin that tears, bruises, or breaks easily)&#xD;
&#xD;
         15. Suffering from current or history of significant skin conditions in the treated area&#xD;
             that could interfere with the evaluation (i.e. infection, dermatitis, or rash on their&#xD;
             face) or requires the use of interfering topical or systemic therapy.&#xD;
&#xD;
         16. Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning&#xD;
             during the study.&#xD;
&#xD;
         17. Having a history of diseases stimulated by heat, such as recurrent Herpes Simplex&#xD;
             (HSV, HZO) in the treated area, unless treatment is conducted following a prophylactic&#xD;
             regimen&#xD;
&#xD;
         18. History of keloid scarring, hypertrophic scarring, or of abnormal wound healing.&#xD;
&#xD;
         19. History of connective tissue diseases such as systemic lupus erythematosus or&#xD;
             scleroderma&#xD;
&#xD;
         20. History of post inflammatory pigmentary disorders, particularly a tendency for hyper-&#xD;
             or hypo-pigmentation.&#xD;
&#xD;
         21. History of cutaneous photosensitization, porphyria, and hypersensitivity to porphyrins&#xD;
             or photodermatosis.&#xD;
&#xD;
         22. Has used photosensitizing drugs (e.g., Declomycin, sulfa antibiotics, phenothiazines,&#xD;
             etc.) within a timeframe where photosensitization from these drugs may still be&#xD;
             present&#xD;
&#xD;
         23. History of skin cancer&#xD;
&#xD;
         24. Change of contraceptives dosing in the past 3 months&#xD;
&#xD;
         25. Medical disorders such as thyroid or kidney diseases&#xD;
&#xD;
         26. Significant concurrent illness or any disease state that in the opinion of the&#xD;
             Investigator would interfere with the treatment or healing process&#xD;
&#xD;
         27. As per the Investigator's discretion, any physical or mental condition which might&#xD;
             make it unsafe for the subject to participate in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mitchel P Goldman, MD</last_name>
    <phone>858.657.1002</phone>
    <email>mgoldman@CLderm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leslie Aguilar</last_name>
    <phone>858.657.1004</phone>
    <phone_ext>120</phone_ext>
    <email>laguilar@clderm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cosmetic Laser Dermatology, A West Dermatology Company</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchel P Goldman, Dr.</last_name>
      <phone>858-657-1002</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 25, 2019</study_first_submitted>
  <study_first_submitted_qc>December 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

